Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Abemaciclib plus Trastuzumab biosimilar (Herzuma) ± Fulvestrant in HER2-positive Breast Cancer with Brain Metastases
KCT0004338Phase 2Not yet recruiting
- Sponsor
- Ministry of Health & Welfare
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib, trastuzumab, fulvestrant in breast cancer, sponsored by Ministry of Health & Welfare. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0004338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004338.